Patient Perspectives on Use of a Water-based Calcipotriene and Betamethasone Dipropionate Cream Formulation for the Treatment of Plaque Psoriasis
Michael A. Vecchiolla, BS,1 Neal Bhatia, MD2 

1EPI Health, LLC, Charleston, SC;  2Therapeutics Clinical Research, San Diego, CA

References
1. Carroll C, et al. Br J Dermatol. 2004;151(4):895-72.
2. Feldman SR, et al. Dermatol Ther (Heidelb). 2021;11(6):2077-88.
3. Curcio A, et al. Improving patient acceptability and adherence in psoriasis 

treatment. Poster presented at the 42nd Annual Fall Clinical Dermatology 
Conference®; October 20-23, 2022; Las Vegas, NV.

4. Armstrong AW, Read C. JAMA. 2020;323(19):1945-60.
5. Wynzora. Prescribing information. EPI Health; 2021. 
6. Praestegaard M, et al. Dermatol Ther (Heidelb). 2022;12(10):2217-31.

Funding Sources and Disclosures 
The patient survey and poster development were funded by EPI Health, a 
Novan company. Dr. Bhatia is a scientific advisor to EPI Health, and Mr. 
Vecchiolla is an EPI Health employee.

• To assess patient satisfaction with CAL/BDP cream applied 
once daily to affected areas

• Patients with plaque psoriasis strongly 
preferred a novel, water-based CAL/BDP 
cream formulation to previously used 
prescription topical therapies

• Most patients reported the CAL/BDP cream 
was well tolerated, moisturized plaques, and 
resulted in visible improvement within 1 
week

• Rapid improvement may limit treatment 
discontinuation rates

• Tolerability of topical therapies is also 
particularly important as some surfactants 
cause skin irritation

• A key benefit of the PAD formulation used in 
WYNZORA cream is a reduced surfactant 
requirement compared to conventional 
emulsion systems

Presented at the 20th Anniversary Winter Clinical Dermatology Conference – Hawaii®; January 13–18, 2023; Kohala Coast, Hawaii. 

Synopsis
• Patient satisfaction with topical medications for the 

treatment of plaque psoriasis is directly related to adherence 
and real-world efficacy1

• Poor cosmetic characteristics and the time-consuming nature 
of greasy topical agents cause up to 75% of patients to 
become nonadherent with topical psoriasis treatments2,3

• Most patients have mild psoriasis that is amenable to topical 
therapies4

• WYNZORA® (calcipotriene [CAL] and betamethasone 
dipropionate [BPD] 0.005%/0.064%) cream is a novel, 
moisturizing, water-based cream formulation5

– Polyaphron dispersion (PAD) technology allows 
formulation and efficient topical delivery of challenging 
molecules while maintaining a favorable aesthetic feel6

– Suitable for psoriasis treatment on both body and scalp6

Objective

Conclusions

Methods

Results

• Patient satisfaction data were collected using a 6-item survey 
about their experiences using the cream

– Included in new patient prescription kits
– Distributed by dermatology healthcare providers in 

November 2021

– Completed 1 week after treatment initiation
• Patients responded using a 5-item Likert scale (strongly agree, 

agree, neutral, disagree, strongly disagree)

• Survey results are based on the pooled number of strongly 
agree, agree, and neutral responses to each survey statement

• 113 adults with plaque psoriasis completed surveys
Baseline Characteristics Patient Perspectives

Figure 4. Mean Duration of 
CAL/BDP Cream Use

10.4 days

Figure 1: Psoriasis Severity

44%
(50/113)
Mild

45%
(51/113)
Moderate

11% (12/113) 
Severe

Figure 2: Psoriasis Treatment Duration
59%

(67/113)
<1 year

41%
(46/113)
>1 year

Figure 3: First Topical Prescription 
Medication for Psoriasis

50%
(57/113)
CAL/BDP 

cream

50%
(56/113)
Othera

• Patient experiences with CAL/BDP cream were positive

0 20 40 60 80 100

96% (108/113)

99% (112/113)

Patients (%)

Observed visible improvement in plaques in 
1 week

Felt better/more confident about their 
plaque psoriasis

Preferred CAL/BDP cream to other topical therapies 
used in the past 

98% (111/113)

Reported it was non-greasy

Stated it helped moisturize their plaques

Reported treatment was well tolerated

95% (107/113)

96% (108/113)

98% (111/113)

96% (108/113)
Would recommend 

the CAL/BDP cream-
based formulation

aOther therapies included topical steroids (n=46); generic 
calcipotriene/betamethasone (n=17); Enstilar® Foam (n=17); 
Duobrii® Lotion (n=15); topical steroids (n=46); Taclonex® (n=10); 
calcipotriene (alone) (n=9); Otezla® (n=5); infused biologics (n=3).

n=38
Torso, lower 

back, legs

Figure 6: Locations of CAL/BDP Cream Use
n=20
Scalp

n=34
Skinfolds 
around
knees 

and/or elbows

n=17
In between 

fingers or toes

n=15
Soles of feet 
and/or palms

n=20
Other

Figure 5. Patient Satisfaction Survey Results